Data gathered: April 15
AI Stock Analysis - Crinetics Pharmaceuticals (CRNX)
Analysis generated July 24, 2024. Powered by Chat GPT.
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company specializes in developing oral nonpeptide small molecule drugs for hormone-dependent diseases. Crinetics operates at the forefront of a competitive and potentially lucrative market, which targets unmet medical needs in the endocrine segment.
Stock Alerts - Crinetics Pharmaceuticals (CRNX)
 |
Crinetics Pharmaceuticals | April 11 Price is up by 7.8% in the last 24h. |
|
Crinetics Pharmaceuticals | April 10 Price is down by -5% in the last 24h. |
|
Crinetics Pharmaceuticals | April 9 Price is down by -5.2% in the last 24h. |
|
Crinetics Pharmaceuticals | April 7 Price is down by -6.6% in the last 24h. |
Alternative Data for Crinetics Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 61 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 17 | Sign up | Sign up | Sign up |
| Patents | 49 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 3 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,134 | Sign up | Sign up | Sign up |
| Instagram Followers | 146 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 816 | Sign up | Sign up | Sign up |
| Twitter Followers | 953 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 90 | Sign up | Sign up | Sign up |
| Linkedin Employees | 424 | Sign up | Sign up | Sign up |
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors.
| Price | $29.78 |
| Target Price | Sign up |
| Volume | 767,110 |
| Market Cap | $2.77B |
| Year Range | $25.56 - $60.69 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Earnings Date | May 8 '25 |
| Industry | Biotechnology |
In the news
 |
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh GottheimerApril 13 - ETF Daily News |
|
JPMorgan Chase & Co. Has $13.78 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)April 13 - ETF Daily News |
|
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of “Moderate Buy” by AnalystsApril 13 - ETF Daily News |
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025April 11 - GlobeNewswire |
|
 |
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10 - Yahoo |
|
Orion Portfolio Solutions LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)April 6 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 26M | -26M | -77M | -87M | -0.960 |
| Q2 '24 | 400,000 | 25M | -24M | -74M | -82M | -0.940 |
| Q1 '24 | 130,000 | 21M | -21M | -67M | -73M | -0.930 |
| Q4 '23 | 0 | 17M | -22M | -60M | -62M | -0.900 |
| Q3 '23 | 350,000 | 15M | -15M | -57M | -59M | -1.010 |
Insider Transactions View All
| Struthers Richard Scott filed to sell 329,147 shares at $34.8. March 21 '25 |
| Betz Stephen F. filed to sell 108,588 shares at $34.8. March 21 '25 |
| Knight Jeff E. filed to sell 87,491 shares at $34.8. March 21 '25 |
| Pizzuti Dana filed to sell 72,233 shares at $34.8. March 21 '25 |
| Betz Stephen F. filed to sell 108,879 shares at $34.2. March 21 '25 |
Similar companies
Read more about Crinetics Pharmaceuticals (CRNX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Crinetics Pharmaceuticals?
The Market Cap of Crinetics Pharmaceuticals is $2.77B.
When does Crinetics Pharmaceuticals report earnings?
Crinetics Pharmaceuticals will report its next earnings on May 8 '25.
What is the current stock price of Crinetics Pharmaceuticals?
Currently, the price of one share of Crinetics Pharmaceuticals stock is $29.78.
How can I analyze the CRNX stock price chart for investment decisions?
The CRNX stock price chart above provides a comprehensive visual representation of Crinetics Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Crinetics Pharmaceuticals shares. Our platform offers an up-to-date CRNX stock price chart, along with technical data analysis and alternative data insights.
Does CRNX offer dividends to its shareholders?
As of our latest update, Crinetics Pharmaceuticals (CRNX) does not offer dividends to its shareholders. Investors interested in Crinetics Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Crinetics Pharmaceuticals?
Some of the similar stocks of Crinetics Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.